Argus raised the firm’s price target on CME Group (CME) to $308 from $285 and keeps a Buy rating on the shares. The firm sees further growth in interest-rate contract volume at CME as inflation fears, tariffs, and geopolitical concerns are at the forefront, the analyst tells investors in a research note. Argus adds that it expects higher volume for equity index, agricultural, cryptocurrency, and micro contracts for retail investors, and also to see CME maintain strong cost controls.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group reports April ADV of 35.9M contracts, a new record
- CME Group (CME) Says It Will Launch Futures Contracts for XRP
- CME Group to expand crypto derivatives suite with launch of XRP Futures
- CME Group price target raised to $273 from $265 at Keefe Bruyette
- CME Group Reports Record Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue